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See Editorial, pages 666–667Background & Aims: Acute intermittent porphyria (AIP) results
from porphobilinogen deaminase (PBGD) haploinsufficiency,
nary PBG and ALA and in the clinical course of the disease were
periodically evaluated prior and after treatment. Viral shedding,which leads to hepatic over-production of the neurotoxic heme
precursors porphobilinogen (PBG) and delta-aminolevulinic acid
(ALA) and the occurrence of neurovisceral attacks. Severe AIP is
a devastating disease that can only be corrected by liver trans-
plantation. Gene therapy represents a promising curative option.
The objective of this study was to investigate the safety of a
recombinant adeno-associated vector expressing PBGD
(rAAV2/5-PBGD) administered for the first time in humans for
the treatment of AIP.
Methods: In this phase I, open label, dose-escalation, multicenter
clinical trial, four cohorts of 2 patients each received a single
intravenous injection of the vector ranging from 5  1011 to
1.8  1013 genome copies/kg. Adverse events and changes in uri-Journal of Hepatology 20
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anxiety inventory.immune response against the vector and vector persistence in
the liver were investigated.
Results: Treatment was safe in all cases. All patients developed
anti-AAV5 neutralizing antibodies but no cellular responses
against AAV5 or PBGD were observed. There was a trend towards
a reduction of hospitalizations and heme treatments, although
ALA and PBG levels remained unchanged. Vector genomes and
transgene expression could be detected in the liver one year after
therapy.
Conclusions: rAAV2/5-PBGD administration is safe but AIP meta-
bolic correction was not achieved at the doses tested in this trial.
Notwithstanding, the treatment had a positive impact in clinical
outcomes in most patients.
Lay summary: Studies in an acute intermittent porphyria (AIP)
animal model have shown that gene delivery of PBGD to
hepatocytes using an adeno-associated virus vector
(rAAV2/5-PBG) prevent mice from suffering porphyria acute
attacks. In this phase I, open label, dose-escalation, multicenter
clinical trial we show that the administration of rAAV2/5-PBGD
to patients with severe AIP is safe but metabolic correction was
not achieved at the doses tested; the treatment, however, had a
positive but heterogeneous impact on clinical outcomes among
treated patients and 2 out of 8 patients have stopped hematin
treatment.
Clinical trial number: The observational phase was registered at
Clinicaltrial.gov as NCT 02076763. The interventional phase
study was registered at EudraCT as n 2011-005590-23 and at
Clinicaltrial.gov as NCT02082860.16 vol. 65 j 776–783
JOURNAL OF HEPATOLOGY 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rAAV2/5-PBGD infusion
Observational phase Interventional phase
6 m 6 m 6 m 6 m
Follow-up
Selection visit 1:
Observational phase
Final visit:
Observational phase
&
Inclusion visit: 
Interventional phase
End of study
visit
Fig. 1. Study design.Introduction
Acute Intermittent Porphyria (AIP) is inherited as an autosomal
dominant disorder of the heme biosynthesis pathway [1,2]. AIP
is caused by a defect in porphobilinogen deaminase (PBGD) gene
which spans 10 kb in chromosome 11q23 [3]. More than 370 dif-
ferent mutations of PBGD have been described, including mis-
sense, nonsense and splicing mutations, as well as deletions
and insertions [4,5].
Heme is synthesized in all body cells but mainly in erythroid
cells and the liver. In AIP, PBGD enzymatic activity is reduced to
about 50% of normal leading to limited capacity to enhance heme
synthesis upon increased biosynthetic demands in the liver [1–3].
5-aminolevulinic acid synthase (ALAS) is the initial and rate-
limiting enzyme of heme biosynthesis. In the liver, the ALAS1
enzyme mediates the reaction of glycine with succinyl-CoA to
yield aminolevulinic acid (ALA), which is transformed into por-
phobilinogen (PBG) by aminolevulinic acid dehydratase. PBGD
mediates the condensation of PBG to hydroxymethylbilane,
which is processed in a stepwise manner to heme, and negatively
controls ALAS1 expression. In AIP subjects the heme deficiency
taking place under conditions of augmented heme requirements
enhances hepatic ALAS1 activity leading to ALA and PBG accumu-
lation [1–3]. These compounds are believed to be responsible for
the complex set of neurotoxic symptoms exhibited by AIP
patients [6].
AIP is characterized by acute episodes and asymptomatic peri-
ods [1,2,6]. AIP patients commonly show high ALA and PBG blood
and urinary levels and their concentrations further increase dur-
ing acute attacks. These episodes are triggered by factors that
activate hepatic heme synthesis including exposure to drugs (like
barbiturates, sulfonamides), hormonal changes, infections or
starvation [1,2,7]. Clinical disease occurs with very low preva-
lence (1 in 185,000) [8], but epidemiologic figures based on the
incidence of acute attacks greatly underestimate the number of
individuals with the genetic defect, which in Sweden is as high
as 1 in 10,000 [9,10] and 1 in 1675 in France [11], indicating that
a large proportion of affected individuals exhibit an asymp-
tomatic form of the disease, in some cases with high ALA and
PBG levels in urine [12,13].
Abdominal pain, frequently accompanied by vomiting, diar-
rhea or constipation, is the most common symptom of acute
attacks. Paresthesia and paralysis also occur, and death may
result from respiratory paralysis. Other symptoms include sei-
zures, psychotic episodes, tachycardia and hypertension
[1,2,7,14]. Current treatment of acute attacks involves
intravenous heme (heme arginate–Normosang in Europe and
lyophilized hematin–Panhematin in USA) infused and/or a
high-carbohydrate diet [15].
Most symptomatic patients have only one attack, but approx-
imately 5% women and 3% men with AIP suffer recurrent and fre-
quent attacks, which persist for many years [6]. This form of
severe AIP is a devastating condition that significantly affects
the quality of life and demands repeated courses of treatment
with heme. Although heme represses ALAS, thus blocking hemeJournal of Hepatology 201biosynthesis, it also activates hemeoxygenase-1 (EC:1.14.99.3),
which in turn promotes acute attack recurrences and the decline
of the therapeutic efficacy [16,17]. Thromboembolic disease and
iron overload (a dose of 250 mg of heme arginate contains
22.7 mg of iron) are also side effects associated with repeated
courses of this therapy [18]. Even though prophylactic heme
appears to be beneficial in patients with recurrent attacks,
life-long exposure to drugs for the control of symptoms may
cause considerable adverse events that greatly impair quality of
life [16,17]. Thus alternative therapies for severe AIP are
needed.
Complete biochemical and symptomatic resolution of AIP was
observed in all patients after liver transplantation [19]. This
observation supports our working hypothesis that therapies
aimed at supplementing hepatocytes with the normal version
of the PBGD gene may correct the disease. Confirming this notion,
our studies in murine AIP models showed that liver-directed gene
therapy using an AAV vector encoding PBGD under the control of
a liver-specific promoter (rAAV2/5-PBGD) was able to restore
hepatic PBGD activity to normal values and prevented the
occurrence of acute attacks [20]. Toxicology studies in mice
(unpublished results) and in non-human primates [21] showed
that the vector could be administered safely even at high doses.
In 2009 the European Medicines Agency granted Orphan Drug
Designation to rAAV2/5-PBGD for the treatment of AIP. Subse-
quently we designed and performed a phase I clinical trial in
patients with severe AIP to assess feasibility, safety and efficacy
of rAAV2/5-PBGD. Here, we report the results of this clinical
study, which is the first gene therapy trial performed in patients
with AIP, and the first to employ an AAV5-based gene therapy
product.Materials and methods
Gene therapy vector
Vector design and production methodologies have already been described
[20,21]. The titer of the virus was determined by quantitative PCR and expressed
as genome copies/ml (gc/ml) [21].
Trial design and objectives
The study was designed as a phase 1, open label, dose-escalation clinical trial.
Since AIP is a rare disease and its clinical presentation very heterogeneous, each
patient served as his/her own control. Thus, the study comprised two different
phases (Fig. 1); one pre-therapy and the other post-therapy (observational and6 vol. 65 j 776–783 777
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interventional phases, respectively). The safety and the efficacy of the treatment
were assessed comparing clinical and biochemical parameters of the observa-
tional and interventional phases.
The primary objective was to assess the safety of the treatment. Secondary
objectives were to assess the effect of the treatment on ALA and PBG urinary
levels, the clinical evolution of the disease, health-related quality of life, and psy-
chological disturbances.
Patients were included and followed-up in two Spanish centers, Clínica
Universidad de Navarra (Pamplona) and Hospital 12 de Octubre (Madrid). All
patients received the treatment at Clínica Universidad de Navarra.
Inclusion and exclusion criteria
Only patients with at least 2 hospital admissions caused by AIP acute attacks or 4
admissions for AIP-specific treatment in the year prior to the initiation of the trial
were included. Exclusion criteria were the presence of liver disease including
hepatitis C or B viral infection, cirrhosis and hepatocellular carcinoma, advanced
renal failure, and presence of neutralizing antibodies against the vector.
Participation in the observational phase for at least 6 months immediately prior
to treatment was required in order to be included in the interventional
phase. Complete inclusion and exclusion criteria are provided in Supplementary
Table 1.
Study procedures
Observational phase
At the selection visit, patients were evaluated by complete medical history
including AIP-specific events such as hospital admissions in the 12 months prior
inclusion and AIP-specific therapies, physical examination, blood tests (blood cell
count, liver and renal function tests, ferritin and a-fetoprotein), urinary ALA and
PBG levels, antibodies against vector and transgene, and genetic confirmation of
AIP. A liver ultrasound was performed to exclude liver malignancies. Patients
were followed-up every 2 months for a minimum of 6 months until their inclu-
sion in the interventional phase. At each follow-up visit, patients were questioned
about the occurrence of AIP-specific symptoms, concomitant medication, in par-
ticular AIP-specific therapies (intravenous heme replacement therapy or glucose
infusions) and the number and duration of AIP-related hospital admissions.
Patients also had routine physical examination and laboratory tests (including
blood cell count, liver and renal function tests, and ALA and PBG urinary levels).
Moreover, patients were asked to collect a urine sample for ALA and PBG mea-
surement between visits in case of acute attack or prior to any AIP-specific treat-
ment. Finally, health-related quality of life and psychological symptoms were
assessed every 2 months using 36-Item Short Form Health Survey (SF-36) version
2 (v2), Beck Depression Inventory II (BDI-II) and Beck Anxiety Inventory (BAI)
questionnaires.
Interventional phase
Recruitment into this phase took place 2 to 4 weeks before administration of the
gene therapy vector and all the assessments performed upon inclusion in the
observational phase were repeated at this time point. Patients were divided into
4 cohorts following the same order of inclusion as in the observational study.
rAAV2/5-PBGD was administered as follows: cohort A (n = 2): 5  1011 gc/kg of
body weight; cohort B (n = 2): 2  1012 gc/kg of body weight; cohort C
(n = 2): 6  1012 gc/kg of body weight; cohort D (n = 2): 1.8  1013 gc/kg of body
weight.
The corresponding dose of rAAV2/5-PBGD was suspended in 0.9% NaCl
solution in a final volume of 20 ml, which was slowly infused through a periph-
eral vein of the arm over 20 minutes. To better evaluate (acute) safety, patients
remained hospitalized for 48 h following vector administration. After discharge
patients were followed-up weekly during the first 8 weeks, fortnightly until week
12, and then monthly until week 48.
Viral shedding was analyzed in biological fluids (blood, urine, semen, oral
and nasal swabs, and stool), as described [21], at 8, 24, 48 h and then at each
visit until viral clearance was confirmed in two consecutive samples. Humoral
and cellular immune responses against the vector and the transgene were
assessed, as described [21] at the selection visit (S) and in visits 1, 2, 3, 4,
8 and 10 and 2, 4, 8 and 10, respectively, after therapy. Blood cell analysis
as well as liver and renal function tests were performed 48 h after the treat-
ment and at each follow-up visit. As during the observational phase, ALA and
PBG urinary levels were determined at each programmed visit and between
visits if the patients experienced an acute attack or received AIP-specific treat-
ment. Medical history and a record of symptoms, concomitant medication
(especially AIP-specific therapies), AIP-related number and duration of hospital778 Journal of Hepatology 201admissions as well as routine physical examination were obtained at each
follow-up visit. AIP patients were requested to fill out SF-36, BAI and BDI
questionnaires every month after the treatment. Additionally, a liver ultra-
sound was performed at the inclusion in the trial and at the end of the
follow-up. Patients will have a liver ultrasound performed every year for
10 years after the gene therapy.
Laboratory studies
ALA and PBG determination in urine sample were performed in a centralized lab-
oratory at Porphyria Centre Sweden, Karolinska University Hospital (Stockholm,
Sweden). Routine blood tests were performed at local laboratories (Hospital 12
de Octubre and Clínica Universidad de Navarra).
Detection of vector DNA sequence in liver samples
Needle liver biopsies were obtained from 6 patients 1 year after treatment. Biop-
sies were frozen in isopentane cooled with liquid nitrogen. Genomic DNA and
total RNA was isolated from liver biopsies using the DNeasy Blood and Tissue
Extraction Kit (Qiagen) and QIAamp RNA Tissue Extraction mini kit. Primers
specific for the boundary between the coPBGD sequences and the polyA element
were used to amplify a sequence specific for the vector DNA and messenger RNA
(mRNA) to differentiate it from the endogenous gene and nRNA as previously
described [21]. To determine endogenous PBGD gene and mRNA copy number
human PBGD specific primers were used. Real-time PCR-based quantification
was performed using SYBR Green master mix (Applied Biosystems, Foster City,
CA). Results were expressed as copy number per lg of total DNA or RNA.
Ethics
Participants gave separate written informed consent for the observational and
interventional phases after the nature and possible consequences of the studies
were explained. The study protocols conform to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori approval by the local Ethics
Committees in Pamplona and Madrid and by the Spanish Agency of Medicines
and Medical Devices. The observational phase was registered at Clinicaltrial.gov
as NCT 02076763. The interventional phase study was registered at EudraCT as
n 2011-005590-23 and at Clinicaltrial.gov as NCT02082860.
Statistical analysis
Differences in clinical and biochemical parameters between the observational
and interventional phases were analyzed using a non-parametric test for paired
values (Wilcoxon test). Aiming to minimize a possible bias due to the different
duration of the follow-up in the observational phase, the changes in ALA and
PBG values and in SF-36, BAI and BDI-II scores were analyzed considering the data
obtained in the first and last semester of the observational phase only. This
applied to all patients except for one belonging to cohort D, who participated
in the observational phase for 6 months only. To assess the effect of the gene ther-
apy on the clinical course of the disease (AIP-hospitalizations and heme infu-
sions), the number of AIP-hospitalizations per month, the number of days of
hospitalization per month and the number of days on heme therapy per month
during the observational and interventional phases were compared in each
patient. p <0.05 was considered statistically significant.Results
Patients
Nine patients, 2 males and 7 females, aged between 33 and
62 years, suffering severe AIP were evaluated. One female patient
was excluded at the initial screening visit because of being posi-
tive for neutralizing antibodies against AAV5. The remaining 8
patients had genetic confirmation of AIP and were recruited to
the observational and the interventional phases of the trial
(Fig. 2).
Six patients were receiving AIP-specific treatment on a sched-
uled manner for the control of chronic symptoms while 26 vol. 65 j 776–783
Table 1. Severe adverse events after treatment.
Type of SAE Time from gene 
therapy
Outcome
Pilonidal cyst surgery 11 weeks Resolved 
Hospital admission for insulin-pump 
infusion placement 
27 weeks Resolved
Myocarditis 28 weeks Resolved
Upper abdominal pain 28 weeks Resolved 
Enrollment
Allocation
Follow-up
Analysis
Assessed for eligibility (n = 9)
Excluded (n = 1)
Not meeting inclusion criteria
Included (n = 8)
Allocated to treatment (n = 8)
Received treatment (n = 8)
Lost to follow-up (n = 0)
Analysed (n = 8)
Fig. 2. Participant’s flow diagram.
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Fig. 3. Aminolevulinc acid (ALA) (A) and porphobilinogen (PBG) (B) urinary
levels before and after rAAV2/5-PBGD administration. Mean values of the first
six months and the last six months of the observational and interventional phases
are shown. Normal urinary levels are <1.5 mmol PBG/mol creatinine and
<3.9 mmol ALA/mol creatinine, respectively.
JOURNAL OF HEPATOLOGYreceived therapy for acute attacks only. Patients were receiving
hematin treatment for a significant period of time prior study
inclusion (median 4.8 years; range 1.5–12.8). The 8 patients were
followed in the observational phase for a median of 14.8 months
(range 6–18 months). They all received rAAV2/5-PBGD and
completed the 48 weeks of follow-up. Clinical data of the patients
are given in Supplementary Table 2.
Safety
rAAV2/5-PBGD administration was well tolerated and no
treatment-related adverse events were observed during follow-
up. Serum transaminases remained within the normal range
throughout the study time except in patient 8 (belonging to
cohort D) who experienced a transient and mild increase of liver
enzymes (alanine aminotransferase (ALT) less than 3 x upper nor-
mal limit) one week after therapy. It coincided with an acute AIP
attack and normalized once the attack had subsided (data not
shown). A total of 4 severe adverse events were observed in 2
patients, however, none of them was related to either gene ther-
apy or study procedures (Table 1).
Immune responses
Patients were analyzed for total and neutralizing antibodies
against AAV5 and total antibodies against the recombinant PBGD
protein at different time points after vector administration. All
developed antibodies against the AAV5 protein capsid capable
of neutralizing AAV5 infectivity (Supplementary Fig. 1). In gen-
eral, the response was dose dependent, except for patient 1
who despite receiving the lowest vector dose, developed the
highest antibody titer, interestingly this patient showed a posi-
tive, although very week, signal in total antibodies againstJournal of Hepatology 201AAV5 at the initial visit of the observational study that was no
detected again. Noteworthy, none of the patients developed anti-
bodies against PBGD recombinant protein (data not shown). No
cellular immune response against the vector or transgene was
detected in any of the patients (Supplementary Table 3).
Viral shedding
We investigated the presence of the virus in serum, urine, stool,
nasal secretion, saliva and semen. Vector shedding analysis in
serum showed maximum vector concentrations 8 h after therapy
(Supplementary Fig. 2). Titers declined thereafter to become
undetectable by day 30 post-injection. Very low levels of
rAAV2/5-PBGD could be transiently detected in saliva, urine,
nasal secretion and faeces, but was undetectable in all patients
by day 30. Importantly, no vector was detected in semen samples,
excluding the risk of germ line transmission in those patients
(Supplementary Fig. 2).
ALA and PBG levels, requirement of AIP-specific therapies and
hospitalizations
Patients showed high levels of urinary ALA and PBG both during
the observational and interventional phases of the study and no
significant changes were observed after rAAV2/5-PBGD adminis-
tration (Fig. 3A, B).
However, a trend towards decreased heme replacement ther-
apy was observed in the interventional phase compared to the
observational period (Fig. 4A). In parallel the number and dura-
tion of hospitalizations also decreased after therapy (Fig. 4B, C).
A noticeable improvement in the symptomatology occurred in
2 patients. One female patient from cohort A, patient 2, who dur-
ing the observational phase was receiving an average of 1–2
heme doses per month for recurrent attacks, stopped hematin
promptly after therapy because of cessation of acute episodes.
However, she continued on oral analgesics and received intra-
venous glucose on 4 occasions for control of milder symptoms.
Also, a male patient, from cohort B, patient 3, who was receiving
hematin infusions every 3 weeks during the observational phase
because of persistent symptoms, stopped hematin 5 weeks after
gene therapy.6 vol. 65 j 776–783 779
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Fig. 5. Changes of Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), and the two main components of SF36 v2 health-related quality of life
questionnaire, physical and mental health, after rAAV2/5-PBGD administration. Each dot represents the mean values of BDI-II (A) and BAI (B) in the first six months and
the last six months of the observational and interventional phases for each patient. The standard cut-off scores of BDI-II are: minimal depression (0–9), mild depression (10–
18); moderate depression (19–29) and severe depression (30–63). The standard cut-off scores of BAI are low anxiety (0–21), moderate anxiety (22–35) and severe anxiety
(36–63). (C, D) Each dot represents the mean values of the two main components of SF36 v2 health-related quality of life questionnaire, physical and mental health in the
first six months and the last six months of the observational phase and of the post-therapy period, respectively, for each patient. According to the SF36 v2 scoring, the lower
the score the more disability, the higher the score the less disability. The median and the standard deviation of the patients’ mean values have been represented and the
differences between the observational and interventional phases were analyzed using a non-parametric test for paired values each variable during the two periods: the
observational and interventional phases.
Research ArticleDepression, anxiety and quality of life
Patients showed a significant improvement of the depression
score (BDI-II) after therapy in comparison to the observational
phase (Fig. 5A) and the anxiety score (BAI-I questionnaire) was
ameliorated in 7 patients and remained unchanged in one case,
patient 3, (Fig. 5B). Moreover, the SF 36 questionnaire, which
evaluates patient health status and overall quality of life, revealed
a significant amelioration of the mental status following
therapy and a better score for physical parameters in 7 patients
(Fig. 5C and D).
Liver transduction
One year after vector administration 6 out of 8 patients volun-
teered to have a liver biopsy for the evaluation of tissue transduc-
tion. Vector genomes were detected in the liver of all tested
patients albeit the copy number was unrelated to the vector dose
(Table 2). Thus, patient 2 from cohort A showed more vector
copies in the liver than patients from cohort B and the number780 Journal of Hepatology 201of vector copies in the liver from the tested patient from cohort
C (patient 5) was higher than in the biopsied patient from cohort
D (patient 7). These findings might reflect sampling variability
due non-homogenous liver transduction or inter-individual dif-
ferences in the susceptibility of the liver to be transduced with
AAV5 vector. As expected no significant differences were
observed in endogenous PBGD gene copy number among
patients. More importantly, vector-derived mRNA expression
was detected in the patients bearing the higher copy number of
vector genomes, patients 2, 5, and 7. The expression of the
recombinant mRNA in those patients is equivalent to 5–7% of
the expression of the endogenous PBGD mRNA.Discussion
In AIP the liver is responsible for excessive production and accu-
mulation of toxic heme precursors, thus playing a key role in the
development of clinically active disease. This notion is supported
by the fact that liver transplantation results in complete6 vol. 65 j 776–783
Table 2. Liver transduction by rAAV2/5-PBGD one year after vector administration.
Patient ID coPBGD DNA exogenous 
(copies/µg) 
PBGD DNA endogenous (copies/
µg)  
coPBGD mRNA exogenous 
(copies/µg) 
PBGD mRNA                
endogenous (copies/µg) 
Pt 1 62.45 29,481.87 ND 1351.36
Pt 2 3394.47 35,440.51 24.98 480.42
Pt 3 109.21 30,333.25 ND 391.90
Pt 4 660.93 47,966.17 ND 179.14
Pt 5 14,280.4 46,166.66 25.64 352.83
Pt 7 2239.7 28,747.73 34.28 686.13
JOURNAL OF HEPATOLOGYmetabolic correction of AIP [19]. However, transplantation is
associated with many complications and requires life-long
immunosuppressive therapy [19]. There clearly is a need for
patients with severe AIP for less invasive therapeutic options
before neurological sequelae become irreversible. In AIP mice
transduction of hepatocytes with gene therapy vectors encoding
PBGD prevented acute attacks upon phenobarbital administra-
tion, suggesting gene therapy as a promising approach for the
treatment of AIP [20,22–24]. Based on these observations we
tested rAAV2/5-PBGD in increasing intravenous doses in 8 AIP
patients divided into 4 cohorts (2 subjects each) from 5  1011
(cohort A) to 1.8  1013 gc/kg (cohort D). All patients included
in the study had at least 2 hospital admissions and/or 4 courses
of AIP-specific therapies for acute attacks in the year previous
to the inclusion visit. Most trial participants had a very severe
form of the disease with chronic symptoms and frequent bouts
of symptomatic aggravation requiring heme replacement
therapy. Our study shows that the therapy was well tolerated.
No serious adverse events related to the AAV5-based vector
administration were observed. As expected all patients generated
neutralizing anti-AAV5 antibodies after therapy but, notably, we
could not detect any cellular immune response - neither against
the transgene nor against the vector capsid. In accordance with
the absence of a cellular immune response against the vector cap-
sid proteins, no transaminase elevation was observed. This was in
contrast to findings in two previous liver-directed gene therapy
trials using AAV serotypes 2 [25,26] and 8 [27] in which the
patients experienced elevations of serum transaminases between
6 to 8 weeks after therapy, likely due to T cell response against
AAV capsid antigen present in transduced hepatocytes. This led
to abrogation or reduction of transgene expression in the first
study and to the use of steroid therapy to preserve the trans-
duced cells in the second study. Interestingly, the doses of vector
employed in the hemophilia trials were nearly 10-fold lower that
the ones employed in our study, the highest dose being
2  1012 gc/kg while in our trial the highest dose was
1.8  1013 gc/kg. The absence of liver damage and anti-capsid T
cell immunity in the present AIP gene therapy trial could be
due to scant immunogenicity of AAV5 compared to AAV2 and
AAV8 or to low liver transduction at the doses used. There are
structural differences between AAV5 and other serotypes, that
can explain the different antigenicity of this vector. Indeed,
according to amino acid sequencing data, AAV5 shares less than
60% of the sequences of AAV2 and AAV8, while the last two ser-
otypes share more than 80% of amino acid sequence identity [28].
An important safety issue of AAV-based gene therapy is the
potential genotoxicity of the vector. This point has been strongly
debated. Donsante et al. [29] showed that treatment of beta-
glucuronidase-deficient mice with a therapeutic AAV vector inJournal of Hepatology 201the neonatal period of life was followed by increased incidence
of HCC. Similarly, Chandler et al. reported a high incidence of
HCC in a mouse model of methyl-malonic acidemia, however,
they also showed that vector dose, the type enhancer/promoter,
and the timing of gene delivery are critical factors for determin-
ing HCC incidence [30]. Furthermore, several other independent
and larger studies in adult mice showed lack of carcinogenicity
of AAV therapeutic vectors [31]. However, recently Nault et al.
reported the presence of integrated wild type (wt) AAV genomes
in HCC samples in 11 out of 193 patients [32]. In our trial AAV
vector was detected in liver biopsies in the six patients tested
one year after therapy but integration analysis using an improved
Multiplex LAM-PCR covering internal and external vector
breakage sites showed that integrations were scarce and ran-
domly distributed [33] and none of them involved the oncogenic
regions reported by Nault et al. [32].
At the vector doses used in the present trial we did not
succeed in reducing ALA and PBG levels. Preclinical studies in
AIP mice showed that therapeutic efficacy with rAAV2/5-PBGD
was attained only at the dose of 1.25  1013 gc/kg [20] which
was similar to the highest one used in the present study. On
the other hand, data from non-human primates [21] indicated
that in order to raise PBGD enzymatic activity in liver tissue over
endogenous levels it was necessary to use a rAAV2/5-PBGD dose
of 5  1013 gc/kg. Thus, seemingly even the doses administered
to cohort D (1.8  1013 gc/kg) were below the therapeutic range,
in fact in those patients in which we could detect transgenic
mRNA in liver tissue, the levels were equivalent to 5–7% of the
endogenous mRNA. New studies with AAV vectors in AIP patients
are clearly warranted. Future trial should employ higher vector
doses, optimized vector design or new serotypes with enhanced
liver transduction efficiency.
Interestingly, the effect of the treatment on clinical outcomes
was very variable among rAAV2/5-PBGD-treated patients. While
two patients, treated in the first and in the second dose cohorts,
experienced a significant clinical improvement leading to marked
reduction in intravenous heme requirements (patients 2 and 3),
among the remaining six patients the beneficial effect on the clin-
ical outcomes was not so clear at least in terms of AIP treatment
requirement. However, most of the participants in the study
scored better in psychometric tests following therapy. These
observations were in contrast with unchanged PBG and ALA
levels. Although this paradox might be explained by a placebo
effect, that may improve the psychometric test scores and also
may lead to a better pain control, it could also be speculated that
the different genetic background resulting in different endoge-
nous PBGD activity may be the reason of this heterogeneity.
The differences in the residual endogenous PBGD activity among
the participants may also explain the lack of a dose-effect relation6 vol. 65 j 776–783 781
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observed in this clinical trial. It should also be noted that some
AIP patients may be asymptomatic despite marked elevation of
heme precursors [12,13].
In summary, the safety and the signs of clinical benefit in a
first in human clinical trial of rAAV2/5-PBGD warrant considera-
tion for future gene therapy trials for AIP.Financial support
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